{"gene":"TNFRSF9","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1993,"finding":"4-1BB is a 30-kDa glycoprotein that exists as both a monomer and a 55-kDa dimer on the T cell surface; cross-linking of 4-1BB on anti-CD3-stimulated T cells dramatically enhanced T cell proliferation, demonstrating its function as an accessory costimulatory signaling molecule.","method":"mAb generation against recombinant soluble 4-1BB, SDS-PAGE, FACS analysis, T cell proliferation assay with cross-linking","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct biochemical characterization (molecular weight, glycoprotein, dimer/monomer), functional cross-linking assay, replicated in multiple T cell types","pmids":["7678621"],"is_preprint":false},{"year":1994,"finding":"Human 4-1BB binds its ligand (4-1BBL) with high affinity (Scatchard analysis); ligation of 4-1BB on T cell clones enhanced activation-induced cell death when triggered alongside TCR/CD3 engagement, whereas mitogen co-stimulation induced strong proliferation.","method":"Molecular cloning, Fc-fusion protein binding assay, Scatchard analysis, proliferation and cell death assays","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — Scatchard binding quantification, functional proliferation and cell death assays in primary T cells, single lab with multiple orthogonal methods","pmids":["8088337"],"is_preprint":false},{"year":1998,"finding":"Human 4-1BB signals are mediated through TRAF1, TRAF2, and TRAF3, which bind to two runs of acidic residues in the cytoplasmic domain of 4-1BB; 4-1BB cross-linking or overexpression activates NF-κB via a TRAF2/NIK pathway, as shown by dominant-negative TRAF2 and NIK inhibition.","method":"Co-immunoprecipitation, mutation analysis of cytoplasmic domain, NF-κB reporter assay in Jurkat and 293 cells, dominant-negative constructs","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — site-directed mutagenesis of binding residues, dominant-negative constructs, NF-κB reporter assay, multiple orthogonal methods in single lab","pmids":["9464265"],"is_preprint":false},{"year":1998,"finding":"4-1BB (CD137) signaling on monocytes induces expression of IL-6, IL-8, and TNF-α, inhibits IL-10, upregulates ICAM, and reduces FcγRIII expression; these effects require immobilized (cross-linked) CD137 protein, indicating they are mediated through a ligand/co-receptor on monocytes — establishing bidirectional signaling.","method":"Cytokine ELISA, flow cytometry for surface receptors, cross-linking assay with immobilized CD137 protein on primary human monocytes","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional readout with cytokine production and surface marker changes, cross-linking requirement shown, single lab with multiple cytokine endpoints","pmids":["9498794"],"is_preprint":false},{"year":1998,"finding":"The 4-1BB signal synergized with CD28 co-stimulation to lower the threshold for T cell activation and IL-2 production; 4-1BB signaling skewed cytokine profiles toward Th1 (markedly enhanced IFN-γ) and suppressed Th2-type cytokines, preferentially in 4-1BB-expressing cells.","method":"T cell co-stimulation assays, intracellular cytokine staining for IFN-γ, cytokine ELISA, flow cytometry","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional assay with intracellular cytokine detection, multiple cytokine endpoints, single lab","pmids":["9541583"],"is_preprint":false},{"year":2000,"finding":"Soluble CD137 (sCD137) expression lags behind membrane-bound CD137 by ~24 h; sCD137 levels correlate negatively with lymphocyte proliferation and positively with activation-induced cell death, suggesting sCD137 may provide a negative regulatory mechanism for immune responses.","method":"Time-course analysis of sCD137 by ELISA, correlation with proliferation assay and activation-induced cell death","journal":"Cytokine","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — correlation analysis with multiple time points and functional outcomes, single lab, no mechanistic intervention experiment","pmids":["10843756"],"is_preprint":false},{"year":2000,"finding":"CD137 is constitutively expressed on primary human monocytes; cross-linking of CD137 on monocytes induces IL-8 and TNF-α production, inhibits IL-10, and causes B lymphocyte apoptosis via direct cell–cell contact.","method":"Flow cytometry, ELISA for cytokines, cell–cell contact co-culture apoptosis assay","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cross-linking experiment, cytokine measurement, B cell apoptosis assay, single lab with multiple endpoints","pmids":["10607752"],"is_preprint":false},{"year":2002,"finding":"4-1BB-deficient mice develop normally but show enhanced T cell proliferation to mitogens/anti-CD3, reduced cytokine production (IL-2, IL-4), diminished CTL activity, and altered myeloid progenitor growth, indicating 4-1BB costimulation is required for normal T cell effector function but restrains proliferation.","method":"Genetic knockout mouse model, in vitro T cell proliferation assay, cytokine ELISA, CTL assay, bone marrow/spleen cell analysis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with defined cellular phenotypes, multiple orthogonal functional readouts, single rigorous study","pmids":["12023342"],"is_preprint":false},{"year":2002,"finding":"4-1BBL is expressed on activated B cells, macrophages, and dendritic cells but not on T cells; 4-1BB is constitutively expressed on splenic dendritic cells and inducible on T cells; 4-1BBL stimulation of dendritic cells leads to IL-6 and IL-12 production and upregulation of co-stimulatory molecules.","method":"Flow cytometry with anti-4-1BB and anti-4-1BBL mAbs, co-culture experiments, cytokine ELISA","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct antibody staining and functional co-culture assays, newly generated blocking mAb, single lab","pmids":["11867564"],"is_preprint":false},{"year":2004,"finding":"Anti-4-1BB agonist antibody treatment suppressed collagen-induced arthritis by inducing expansion of CD11c+CD8+ T cells; IFN-γ produced by these cells suppressed antigen-specific CD4+ T cells through an indoleamine 2,3-dioxygenase (IDO)-dependent mechanism, as shown by anti-IFN-γ and 1-methyltryptophan reversal.","method":"In vivo murine CIA model, antibody treatment, IDO inhibitor (1-methyltryptophan), anti-IFN-γ blocking, flow cytometry for T cell subsets","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic and pharmacological interventions, multiple orthogonal mechanistic tools (IDO inhibitor + anti-IFN-γ), established cell subset expansion","pmids":["15448685"],"is_preprint":false},{"year":2005,"finding":"4-1BB (CD137) is required for rapid clearance of Listeria monocytogenes; 4-1BB-deficient mice showed impaired neutrophil reactive oxygen species generation, phagocytosis, and intracellular Ca2+ mobilization; 4-1BB ligation on neutrophils induced Ca2+ influx.","method":"4-1BB KO mice, bacterial infection model, ROS assay, phagocytosis assay, Ca2+ influx measurement, anti-4-1BB mAb treatment","journal":"Infection and immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO plus antibody agonism, multiple functional neutrophil readouts, in vivo bacterial burden quantification","pmids":["16041031"],"is_preprint":false},{"year":2010,"finding":"4-1BB signaling in the periphery negatively regulates NK cell development through IFN-γ produced by peripheral CD8+ T and NK cells; this IFN-γ suppresses NK cell development in the bone marrow, shifting antitumor immunity from innate NK cell to adaptive CD8+ T cell dominance.","method":"4-1BB KO mice, tumor challenge models, flow cytometry for NK cell frequency in spleen/bone marrow, IFN-γ neutralization","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO, IFN-γ neutralization in vivo, cellular analysis in multiple compartments, mechanistic pathway established","pmids":["20610645"],"is_preprint":false},{"year":2017,"finding":"Tonic 4-1BB signaling in CAR-T cells causes T cell toxicity via continuous TRAF2-dependent NF-κB activation and augmented FAS-dependent cell death; this was amplified by non-self-inactivating gammaretroviral vectors through positive feedback on the LTR promoter.","method":"CAR-T cell cultures, NF-κB reporter assay, TRAF2 knockdown, FAS pathway analysis, comparison of lentiviral vs. retroviral vectors","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway defined via TRAF2 knockdown, NF-κB activation assay, FAS pathway analysis, vector comparison, single lab with multiple orthogonal methods","pmids":["28978471"],"is_preprint":false},{"year":2018,"finding":"4-1BB (CD137) costimulation induces mitochondrial enlargement, increasing mitochondrial mass and transmembrane potential in CD8+ T cells; this depends on mitochondrial fusion protein OPA-1 expression, enhances respiratory capacity, and is required for anti-tumor efficacy in adoptive T cell therapy.","method":"Mitochondrial staining (MitoTracker), transmission electron microscopy, OPA-1 knockout cells, oxygen consumption assay, in vivo adoptive transfer tumor model","journal":"Cancer immunology research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — OPA-1 genetic requirement established, metabolic measurements, in vivo functional readout, multiple orthogonal methods in single study","pmids":["29678874"],"is_preprint":false},{"year":2018,"finding":"4-1BB enhancement of CAR-T cell function is driven by NF-κB activation; TRAF1 and TRAF3 (in addition to TRAF2) are critical for 4-1BB costimulation in CAR-T cells, impacting viability, proliferation, cytotoxicity, and cytokine production.","method":"TRAF knockdown in CD19-CAR T cells, NF-κB reporter assay, cytotoxicity assay, cytokine ELISA, proliferation assay","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Moderate — TRAF knockdown experiments for each TRAF family member, NF-κB reporter, multiple functional readouts, single lab with multiple orthogonal methods","pmids":["30232281"],"is_preprint":false},{"year":2018,"finding":"Activation of 4-1BB on liver myeloid cells (Kupffer cells and monocytes) is essential to initiate 4-1BB agonist-induced hepatitis; these cells produce IL-27 required for liver toxicity; CD8+ T cells then infiltrate and mediate tissue damage; FoxP3+ Tregs limit damage.","method":"Immunocompetent mice with KO for specific cytokines/chemokines, flow cytometry, serum transaminase measurement, in vivo depletion studies, CCR2-KO mice","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple KO models, specific cytokine/chemokine pathway identified, cell subset depletion, mechanistic pathway established in vivo","pmids":["29301830"],"is_preprint":false},{"year":2018,"finding":"The crystal structure of the human 4-1BB/4-1BBL complex at 2.4-Å resolution shows 4-1BBL forms a canonical bell-shaped trimer typical of TNF superfamily members (not the unusual three-bladed propeller reported previously); mutational data confirmed biological relevance of this structure.","method":"X-ray crystallography at 2.4-Å resolution, site-directed mutagenesis to validate interface","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with functional mutagenesis validation, definitive structural determination","pmids":["29720399"],"is_preprint":false},{"year":2019,"finding":"CD137/4-1BB deficiency (homozygous biallelic loss-of-function mutation G109S abolishing protein expression) resulted in impaired CD8+ T cell expansion, reduced IFN-γ and perforin expression, diminished cytotoxicity against EBV-B cells, and significantly reduced mitochondrial biogenesis, membrane potential, and function in activated T cells.","method":"Whole-exome sequencing, immunoblotting, immunophenotyping, in vitro cytotoxicity assays, mitochondrial function assays, inhibitory antibody recapitulation experiments","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — human loss-of-function mutation, multiple orthogonal functional and metabolic assays, antibody recapitulation confirming mechanistic specificity","pmids":["30872117"],"is_preprint":false},{"year":2019,"finding":"PIK3CD and TNFRSF9 (CD137) deficiency together cause chronic active EBV infection of T cells; isolated CD137 deficiency caused persistent EBV-infected T cells, demonstrating CD137 is specifically required for controlling EBV-infected T cell accumulation via T cell expansion through the CD137-CD137L pathway.","method":"Genetic sequencing identifying biallelic loss-of-function mutations, flow cytometry, in vitro T cell expansion assay with CD137L-expressing cells","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — human genetic loss-of-function, sibling comparison (isolated CD137 deficiency), functional T cell expansion assay, clear pathway placement","pmids":["31537641"],"is_preprint":false},{"year":2019,"finding":"Oncogenic K-Ras upregulates CD137 in pancreatic cancer cells through activation of MAPK and NF-κB pathways, with NF-κB being mainly stimulated by K-Ras-induced IL-1α secretion that promotes CD137 gene transcription.","method":"Inducible K-RasG12V expression system, siRNA knockdown of MAPK1 and p65, RT-PCR, flow cytometry, ELISA","journal":"Cancer communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inducible expression system and siRNA knockdown with multiple pathway inhibitions, single lab, in vitro model","pmids":["31288851"],"is_preprint":false},{"year":2021,"finding":"CD137 costimulation provided in cis (on the same cell as TCR-CD3 ligation) is superior to trans costimulation in terms of T cell activation, proliferation, survival, cytokine secretion, and mitochondrial fitness; cis CD137 ligation results in more intense canonical and non-canonical NF-κB signaling and stronger induction of cell cycle and DNA damage repair gene expression.","method":"Side-by-side comparison of cis vs. trans CD137 costimulation in vitro and in vivo, NF-κB signaling assays, gene expression profiling, mitochondrial fitness assays in mouse and human T cells","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — controlled side-by-side comparison, NF-κB pathway measurement, in vivo validation, replicated in mouse and human, multiple orthogonal endpoints","pmids":["34911975"],"is_preprint":false},{"year":2021,"finding":"CD137 stimulation enhances tumoricidal activity of human monocytes/macrophages through an ERK-dependent mechanism, inducing metabolic reprogramming and a functional skewing toward M1-like phenotype; CD137-high monocytes show increased antibody-dependent phagocytosis.","method":"Flow cytometry, transcriptomic analysis, ERK inhibition, phagocytosis assay, metabolic profiling of primary human monocytes","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ERK inhibitor mechanistic experiment, functional phagocytosis and metabolic assays, transcriptomic analysis, single lab","pmids":["34021248"],"is_preprint":false},{"year":2021,"finding":"ADAM10 (and potentially ADAM17) mediates ectodomain shedding of CD137 to generate soluble CD137 (sCD137); inhibition of ADAM10 uniformly blocked sCD137 release from transfected cell lines and primary T cells; phosphatidylserine exposure (controlled by ANO6 scramblase) modulates ADAM10-dependent shedding.","method":"ADAM10 inhibitors, ANO6 overexpression, sCD137 ELISA, primary T cell experiments","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition and overexpression experiments, multiple cell systems, single lab","pmids":["33800462"],"is_preprint":false},{"year":2023,"finding":"T cell-intrinsic, TCR-independent CD137 signaling stimulates proliferation and terminal differentiation of exhausted CD8+ T (Tex) precursor cells through RelA and cRel canonical NF-κB subunits and Tox-dependent chromatin remodeling.","method":"T cell-specific CD137 deletion (genetic KO), agonist antibody treatment, NF-κB subunit analysis (RelA, cRel), chromatin accessibility assay, flow cytometry for exhaustion markers in mouse tumor models","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — T cell-specific genetic deletion, NF-κB subunit identification, Tox chromatin remodeling mechanism, multiple orthogonal approaches in single rigorous study","pmids":["37392737"],"is_preprint":false},{"year":2024,"finding":"4-1BB incorporated within CAR constructs sequesters the ubiquitin-modifying enzyme A20 to the cell membrane in a TRAF-dependent manner, causing A20 functional deficiency that leads to NF-κB hyperactivity, ICAM-1 overexpression, cell aggregation, and cell death via RIPK1/RIPK3/MLKL necroptosis pathway; overexpressing A20 or deleting TRAF-binding motifs of 4-1BB rescued this phenotype.","method":"Mechanistic studies with A20 overexpression, deletion of TRAF-binding motifs in 4-1BB, co-immunoprecipitation, NF-κB reporter assay, RIPK1/RIPK3/MLKL pathway analysis, cell death and aggregation assays","journal":"Cellular & molecular immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — site-directed mutagenesis of TRAF-binding motifs, A20 overexpression rescue, Co-IP for complex formation, multiple mechanistic readouts, single lab with orthogonal approaches","pmids":["38937625"],"is_preprint":false},{"year":2014,"finding":"4-1BBL expressed on T cells can transmit reverse signals that limit T cell effector activity; cross-linking 4-1BBL inhibited IL-2 production, and APC-derived 4-1BB triggers 4-1BBL on T cells; T cell-intrinsic 4-1BB regulated internalization of membrane 4-1BBL, controlling the suppressive function of 4-1BBL.","method":"4-1BBL-deficient T cell transfers, 4-1BB-deficient host experiments, in vitro cross-linking assay, Ab capture and endocytosis experiments, flow cytometry","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO host and T cell transfers, endocytosis experiments, multiple orthogonal approaches, single lab","pmids":["25404362"],"is_preprint":false},{"year":2017,"finding":"CD137 costimulation with agonist mAb (including urelumab) induces genome-wide DNA methylation changes in human CD8+ T cells, altering expression of immune-related genes including CD96, HHLA2, CCR5, CXCR5, and CCL5, as well as TCF1 transcription factor and miR-21 via methylation-dependent regulation.","method":"Genome-wide DNA methylation arrays, pyrosequencing validation, mRNA and protein expression analysis in human peripheral blood CD8+ T cells","journal":"Cancer immunology research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide methylation arrays plus pyrosequencing validation across multiple donors, mRNA/protein confirmation, single lab","pmids":["29133290"],"is_preprint":false}],"current_model":"TNFRSF9/CD137/4-1BB is an activation-inducible TNFR superfamily receptor that lacks intrinsic kinase activity and signals through recruitment of TRAF1, TRAF2, and TRAF3 to acidic residues in its cytoplasmic domain, activating canonical NF-κB via TRAF2/NIK, driving T cell survival, proliferation, Th1 cytokine production, and mitochondrial biogenesis (dependent on OPA-1-mediated fusion); it also undergoes ADAM10-mediated ectodomain shedding to produce soluble CD137, and engages in bidirectional signaling where 4-1BBL reverse signaling into APCs and T cells can limit T cell activation; in CAR-T cells, ectopic 4-1BB domain sequesters A20 in a TRAF-dependent manner, causing NF-κB hyperactivity and necroptosis via RIPK1/RIPK3/MLKL, while in exhausted T cells TCR-independent CD137 signaling drives proliferation and terminal differentiation through RelA/cRel NF-κB and Tox-dependent chromatin remodeling."},"narrative":{"mechanistic_narrative":"TNFRSF9 (4-1BB/CD137) is an activation-inducible TNF receptor superfamily costimulatory receptor that amplifies T cell effector responses upon engagement of its ligand 4-1BBL [PMID:7678621, PMID:8088337, PMID:29720399]. Lacking intrinsic enzymatic activity, the receptor signals through its cytoplasmic domain, where two runs of acidic residues recruit TRAF1, TRAF2, and TRAF3 to drive canonical NF-κB activation via a TRAF2/NIK axis [PMID:9464265], and all three TRAFs contribute to its costimulatory output [PMID:30232281]. Productive signaling lowers the threshold for T cell activation in synergy with CD28, skews cytokines toward Th1 (notably IFN-γ), supports CD8+ T cell expansion and cytotoxicity, and reprograms metabolism by inducing OPA-1-dependent mitochondrial biogenesis and respiratory capacity [PMID:9541583, PMID:29678874, PMID:34911975]. Costimulation delivered in cis (on the same cell as TCR-CD3 ligation) produces more intense canonical and non-canonical NF-κB signaling than trans engagement [PMID:34911975], and TCR-independent CD137 signaling drives proliferation and terminal differentiation of exhausted CD8+ T cells through RelA/cRel NF-κB and Tox-dependent chromatin remodeling [PMID:37392737]. The receptor also acts beyond T cells: it is constitutively expressed on monocytes and signals bidirectionally to induce inflammatory cytokines and macrophage tumoricidal activity [PMID:9498794, PMID:10607752, PMID:34021248], and it is required for normal neutrophil microbicidal function [PMID:16041031]. Biallelic loss-of-function mutations in TNFRSF9 abolish protein expression and cause defective CD8+ T cell expansion, cytotoxicity, and mitochondrial function, manifesting as failure to control EBV-infected T cells (chronic active EBV infection) [PMID:30872117, PMID:31537641]. The receptor undergoes ADAM10-mediated ectodomain shedding to generate soluble CD137 [PMID:33800462], and within CAR-T constructs the 4-1BB domain can drive toxicity by TRAF-dependent sequestration of A20, producing NF-κB hyperactivity and RIPK1/RIPK3/MLKL necroptosis [PMID:28978471, PMID:38937625].","teleology":[{"year":1993,"claim":"Established that 4-1BB is a cell-surface glycoprotein on T cells whose cross-linking costimulates proliferation, defining it as an accessory signaling molecule rather than a passive marker.","evidence":"mAb generation, SDS-PAGE/FACS biochemistry, and T cell proliferation assays with cross-linking","pmids":["7678621"],"confidence":"High","gaps":["Ligand identity and binding affinity not yet defined","No intracellular signaling pathway identified"]},{"year":1994,"claim":"Quantified high-affinity 4-1BB/4-1BBL binding and showed signaling outcome is context-dependent, enhancing proliferation under mitogen but augmenting activation-induced cell death with TCR engagement.","evidence":"Cloning, Fc-fusion binding with Scatchard analysis, proliferation and cell death assays in primary T cells","pmids":["8088337"],"confidence":"High","gaps":["Molecular basis of the proliferation-versus-death switch unresolved","Downstream signaling effectors not identified"]},{"year":1998,"claim":"Defined the proximal signaling mechanism, showing acidic cytoplasmic residues recruit TRAF1/2/3 to activate NF-κB through TRAF2/NIK, placing 4-1BB in the canonical TNFR signaling framework.","evidence":"Co-IP, cytoplasmic-domain mutagenesis, NF-κB reporter and dominant-negative TRAF2/NIK in Jurkat and 293 cells","pmids":["9464265"],"confidence":"High","gaps":["Relative contributions of individual TRAFs not separated","Non-canonical NF-κB role not addressed"]},{"year":1998,"claim":"Extended 4-1BB function to costimulatory quality and beyond T cells, showing synergy with CD28, Th1 cytokine skewing, and bidirectional signaling that activates monocytes through a co-receptor on those cells.","evidence":"Intracellular cytokine staining, ELISA, and cross-linking with immobilized CD137 on primary monocytes","pmids":["9541583","9498794"],"confidence":"Medium","gaps":["Monocyte counter-receptor for CD137 not molecularly identified","Bidirectional signaling components on monocytes undefined"]},{"year":2000,"claim":"Identified soluble CD137 as a delayed, potentially negative regulatory output correlating with reduced proliferation and increased activation-induced cell death.","evidence":"Time-course sCD137 ELISA correlated with proliferation and cell death readouts","pmids":["10843756","10607752"],"confidence":"Medium","gaps":["No causal intervention demonstrating sCD137 function","Protease generating sCD137 not yet identified"]},{"year":2002,"claim":"Genetic loss-of-function in mice resolved the in vivo physiological role, showing 4-1BB is required for normal effector cytokine production and CTL activity while paradoxically restraining proliferation.","evidence":"4-1BB knockout mice with proliferation, cytokine, CTL, and myeloid progenitor assays","pmids":["12023342","11867564"],"confidence":"High","gaps":["Cell-type-specific contributions not dissected","Mechanism of proliferation restraint unexplained"]},{"year":2005,"claim":"Demonstrated a non-T-cell innate role, with 4-1BB required for neutrophil ROS production, phagocytosis, and calcium mobilization for bacterial clearance.","evidence":"4-1BB KO mice in Listeria infection with ROS, phagocytosis, and Ca2+ assays plus agonist mAb","pmids":["16041031"],"confidence":"High","gaps":["Neutrophil signaling pathway downstream of 4-1BB not defined","Ligand source in vivo not established"]},{"year":2010,"claim":"Showed 4-1BB shapes immune-compartment balance, with peripheral signaling driving IFN-γ that suppresses bone marrow NK development and shifts antitumor immunity toward CD8+ T cells.","evidence":"4-1BB KO mice, tumor challenge, compartmental flow cytometry, IFN-γ neutralization","pmids":["20610645","15448685"],"confidence":"High","gaps":["Direct versus indirect effects on NK progenitors not separated","IDO/IFN-γ regulatory circuit in other settings not generalized"]},{"year":2018,"claim":"Linked 4-1BB costimulation to metabolic reprogramming, establishing OPA-1-dependent mitochondrial biogenesis and respiratory capacity as required for antitumor T cell efficacy.","evidence":"MitoTracker, electron microscopy, OPA-1 knockout, oxygen consumption, and adoptive transfer tumor model","pmids":["29678874"],"confidence":"High","gaps":["Signaling link from NF-κB to OPA-1 not mapped","Whether shedding regulates this metabolic program unknown"]},{"year":2018,"claim":"Resolved the structural basis of receptor-ligand engagement, showing 4-1BBL forms a canonical TNF-superfamily bell-shaped trimer, correcting an earlier propeller model.","evidence":"2.4-Å X-ray crystallography of the 4-1BB/4-1BBL complex with interface mutagenesis","pmids":["29720399"],"confidence":"High","gaps":["Stoichiometry of higher-order signaling clusters not defined","Conformational changes transmitting signal to cytoplasm not shown"]},{"year":2019,"claim":"Established human disease causality, with biallelic loss-of-function mutations abolishing CD137 expression and producing defective CD8+ T cell expansion, cytotoxicity, mitochondrial function, and failure to control EBV-infected T cells.","evidence":"Whole-exome sequencing, immunoblotting, cytotoxicity and mitochondrial assays, antibody recapitulation, and T cell expansion with CD137L-expressing cells","pmids":["30872117","31537641"],"confidence":"High","gaps":["Tissue-specific consequences beyond T cells in patients not characterized","Genetic interaction with PIK3CD not fully separated in all cases"]},{"year":2017,"claim":"Revealed an epigenetic dimension to CD137 costimulation, showing agonist signaling reprograms genome-wide DNA methylation to alter immune-gene and transcription-factor expression.","evidence":"Genome-wide methylation arrays with pyrosequencing and mRNA/protein validation in human CD8+ T cells","pmids":["29133290"],"confidence":"Medium","gaps":["Enzymes mediating methylation changes not identified","Causality between methylation and phenotype not fully demonstrated"]},{"year":2021,"claim":"Clarified signaling geometry and a defined shedding mechanism, showing cis costimulation outperforms trans and that ADAM10 mediates ectodomain shedding to generate soluble CD137 under phosphatidylserine-regulated control.","evidence":"Cis-versus-trans comparisons with NF-κB and mitochondrial assays; ADAM10 inhibitors and ANO6 overexpression with sCD137 ELISA","pmids":["34911975","33800462","34021248"],"confidence":"High","gaps":["Physiological trigger of cis presentation in vivo not defined","Function of sCD137 generated by ADAM10 not causally tested"]},{"year":2023,"claim":"Identified a TCR-independent CD137 signaling program that drives proliferation and terminal differentiation of exhausted CD8+ T cells via RelA/cRel NF-κB and Tox-dependent chromatin remodeling.","evidence":"T cell-specific CD137 deletion, agonist treatment, NF-κB subunit analysis, and chromatin accessibility assays in mouse tumor models","pmids":["37392737"],"confidence":"High","gaps":["Ligand source for TCR-independent signaling not defined","Reversibility of Tox-driven terminal differentiation unknown"]},{"year":2024,"claim":"Defined a toxicity mechanism intrinsic to 4-1BB-containing CAR constructs, where TRAF-dependent membrane sequestration of A20 causes NF-κB hyperactivity and RIPK1/RIPK3/MLKL necroptosis.","evidence":"TRAF-binding motif deletion, A20 overexpression rescue, Co-IP, NF-κB reporter, and necroptosis pathway analysis in CAR-T cells","pmids":["38937625","28978471","30232281"],"confidence":"High","gaps":["Threshold of tonic signaling triggering necroptosis not quantified","Whether native 4-1BB engages A20 similarly not established"]},{"year":null,"claim":"How the receptor's signaling outputs are switched between costimulatory survival, activation-induced death, metabolic reprogramming, and necroptotic toxicity by ligand geometry, TRAF stoichiometry, and shedding remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model integrating cis/trans presentation with downstream effector choice","Counter-receptor mediating monocyte bidirectional signaling unidentified","Causal function of soluble CD137 in vivo undetermined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[1,16]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,14]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,6,8]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,7,23]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,14,20]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[24]}],"complexes":[],"partners":["TNFSF9","TRAF1","TRAF2","TRAF3","TNFAIP3","ADAM10"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q07011","full_name":"Tumor necrosis factor receptor superfamily member 9","aliases":["4-1BB ligand receptor","CDw137","T-cell antigen 4-1BB homolog","T-cell antigen ILA"],"length_aa":255,"mass_kda":27.9,"function":"Receptor for TNFSF9/4-1BBL. Conveys a signal that enhances CD8(+) T-cell survival, cytotoxicity, and mitochondrial activity, thereby promoting immunity against viruses and tumors (Probable)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q07011/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFRSF9","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFRSF9","total_profiled":1310},"omim":[{"mim_id":"620282","title":"IMMUNODEFICIENCY 109 WITH LYMPHOPROLIFERATION; IMD109","url":"https://www.omim.org/entry/620282"},{"mim_id":"610424","title":"HEPATITIS B VIRUS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/610424"},{"mim_id":"609193","title":"LEUCINE-RICH REPEAT PROTEIN 1; LRR1","url":"https://www.omim.org/entry/609193"},{"mim_id":"606182","title":"TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 9; TNFSF9","url":"https://www.omim.org/entry/606182"},{"mim_id":"602839","title":"PHOSPHATIDYLINOSITOL 3-KINASE, CATALYTIC, DELTA; PIK3CD","url":"https://www.omim.org/entry/602839"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Nucleoli","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":9.2}],"url":"https://www.proteinatlas.org/search/TNFRSF9"},"hgnc":{"alias_symbol":["CD137","4-1BB"],"prev_symbol":["ILA"]},"alphafold":{"accession":"Q07011","domains":[{"cath_id":"2.10.50.10","chopping":"28-86","consensus_level":"medium","plddt":93.4678,"start":28,"end":86},{"cath_id":"2.10.50.10","chopping":"106-164","consensus_level":"medium","plddt":93.9953,"start":106,"end":164}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07011","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q07011-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q07011-F1-predicted_aligned_error_v6.png","plddt_mean":82.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFRSF9","jax_strain_url":"https://www.jax.org/strain/search?query=TNFRSF9"},"sequence":{"accession":"Q07011","fasta_url":"https://rest.uniprot.org/uniprotkb/Q07011.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q07011/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07011"}},"corpus_meta":[{"pmid":"25939063","id":"PMC_25939063","title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.","date":"2015","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25939063","citation_count":1471,"is_preprint":false},{"pmid":"29321369","id":"PMC_29321369","title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/29321369","citation_count":469,"is_preprint":false},{"pmid":"29118009","id":"PMC_29118009","title":"Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/29118009","citation_count":383,"is_preprint":false},{"pmid":"7678621","id":"PMC_7678621","title":"Inducible T cell antigen 4-1BB. Analysis of expression and function.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7678621","citation_count":357,"is_preprint":false},{"pmid":"34230645","id":"PMC_34230645","title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.","date":"2021","source":"Nature reviews. Clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34230645","citation_count":307,"is_preprint":false},{"pmid":"15448685","id":"PMC_15448685","title":"4-1BB-mediated immunotherapy of rheumatoid arthritis.","date":"2004","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15448685","citation_count":259,"is_preprint":false},{"pmid":"19426223","id":"PMC_19426223","title":"Immune regulation by 4-1BB and 4-1BBL: complexities and challenges.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19426223","citation_count":251,"is_preprint":false},{"pmid":"9826581","id":"PMC_9826581","title":"Role of 4-1BB in immune responses.","date":"1998","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9826581","citation_count":238,"is_preprint":false},{"pmid":"21074066","id":"PMC_21074066","title":"Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.","date":"2010","source":"Seminars in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21074066","citation_count":230,"is_preprint":false},{"pmid":"28978471","id":"PMC_28978471","title":"Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28978471","citation_count":224,"is_preprint":false},{"pmid":"11867564","id":"PMC_11867564","title":"Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells.","date":"2002","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11867564","citation_count":219,"is_preprint":false},{"pmid":"8088337","id":"PMC_8088337","title":"Molecular and biological characterization of human 4-1BB and its ligand.","date":"1994","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8088337","citation_count":216,"is_preprint":false},{"pmid":"26106583","id":"PMC_26106583","title":"4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.","date":"2015","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26106583","citation_count":205,"is_preprint":false},{"pmid":"12787564","id":"PMC_12787564","title":"Costimulation of T cells by OX40, 4-1BB, and CD27.","date":"2003","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12787564","citation_count":188,"is_preprint":false},{"pmid":"12023342","id":"PMC_12023342","title":"Immune responses in 4-1BB (CD137)-deficient mice.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12023342","citation_count":172,"is_preprint":false},{"pmid":"9498794","id":"PMC_9498794","title":"CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9498794","citation_count":157,"is_preprint":false},{"pmid":"9464265","id":"PMC_9464265","title":"Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9464265","citation_count":141,"is_preprint":false},{"pmid":"22532596","id":"PMC_22532596","title":"Immunotherapy of cancer with 4-1BB.","date":"2012","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/22532596","citation_count":140,"is_preprint":false},{"pmid":"30232281","id":"PMC_30232281","title":"4-1BB enhancement of CAR T function requires NF-κB and TRAFs.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/30232281","citation_count":136,"is_preprint":false},{"pmid":"23414607","id":"PMC_23414607","title":"The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.","date":"2013","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23414607","citation_count":132,"is_preprint":false},{"pmid":"7849293","id":"PMC_7849293","title":"ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7849293","citation_count":127,"is_preprint":false},{"pmid":"32611557","id":"PMC_32611557","title":"New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis.","date":"2020","source":"ESMO open","url":"https://pubmed.ncbi.nlm.nih.gov/32611557","citation_count":121,"is_preprint":false},{"pmid":"31105267","id":"PMC_31105267","title":"Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31105267","citation_count":121,"is_preprint":false},{"pmid":"21217771","id":"PMC_21217771","title":"4-1BB signaling beyond T cells.","date":"2011","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21217771","citation_count":119,"is_preprint":false},{"pmid":"25908780","id":"PMC_25908780","title":"Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25908780","citation_count":112,"is_preprint":false},{"pmid":"9541583","id":"PMC_9541583","title":"Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses.","date":"1998","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9541583","citation_count":112,"is_preprint":false},{"pmid":"20176988","id":"PMC_20176988","title":"CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice.","date":"2010","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/20176988","citation_count":109,"is_preprint":false},{"pmid":"14671675","id":"PMC_14671675","title":"Role of 4-1BB:4-1BB ligand in cancer immunotherapy.","date":"2004","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/14671675","citation_count":108,"is_preprint":false},{"pmid":"26773716","id":"PMC_26773716","title":"Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.","date":"2016","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26773716","citation_count":107,"is_preprint":false},{"pmid":"24499671","id":"PMC_24499671","title":"4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy.","date":"2014","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/24499671","citation_count":107,"is_preprint":false},{"pmid":"27034234","id":"PMC_27034234","title":"4-1BB agonism: adding the accelerator to cancer immunotherapy.","date":"2016","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/27034234","citation_count":102,"is_preprint":false},{"pmid":"30524423","id":"PMC_30524423","title":"CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30524423","citation_count":92,"is_preprint":false},{"pmid":"18364008","id":"PMC_18364008","title":"The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.","date":"2008","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/18364008","citation_count":91,"is_preprint":false},{"pmid":"37392737","id":"PMC_37392737","title":"TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation.","date":"2023","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/37392737","citation_count":90,"is_preprint":false},{"pmid":"29301830","id":"PMC_29301830","title":"Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29301830","citation_count":85,"is_preprint":false},{"pmid":"18599129","id":"PMC_18599129","title":"Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies.","date":"2008","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/18599129","citation_count":83,"is_preprint":false},{"pmid":"31537641","id":"PMC_31537641","title":"Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells.","date":"2019","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31537641","citation_count":80,"is_preprint":false},{"pmid":"36727218","id":"PMC_36727218","title":"The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy.","date":"2023","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/36727218","citation_count":79,"is_preprint":false},{"pmid":"29678874","id":"PMC_29678874","title":"Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.","date":"2018","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/29678874","citation_count":77,"is_preprint":false},{"pmid":"30872117","id":"PMC_30872117","title":"Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency.","date":"2019","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30872117","citation_count":70,"is_preprint":false},{"pmid":"10946324","id":"PMC_10946324","title":"Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10946324","citation_count":70,"is_preprint":false},{"pmid":"10607752","id":"PMC_10607752","title":"CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes.","date":"2000","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10607752","citation_count":69,"is_preprint":false},{"pmid":"36576322","id":"PMC_36576322","title":"CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary.","date":"2023","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/36576322","citation_count":68,"is_preprint":false},{"pmid":"26751393","id":"PMC_26751393","title":"Rationale for anti-CD137 cancer immunotherapy.","date":"2016","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/26751393","citation_count":68,"is_preprint":false},{"pmid":"31013788","id":"PMC_31013788","title":"An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31013788","citation_count":67,"is_preprint":false},{"pmid":"15979409","id":"PMC_15979409","title":"Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation.","date":"2005","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15979409","citation_count":63,"is_preprint":false},{"pmid":"15618293","id":"PMC_15618293","title":"Biological activities of reverse signal transduction through CD137 ligand.","date":"2004","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/15618293","citation_count":62,"is_preprint":false},{"pmid":"39888270","id":"PMC_39888270","title":"Quercetin-Driven Akkermansia Muciniphila Alleviates Obesity by Modulating Bile Acid Metabolism via an ILA/m6A/CYP8B1 Signaling.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39888270","citation_count":60,"is_preprint":false},{"pmid":"34911975","id":"PMC_34911975","title":"CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34911975","citation_count":60,"is_preprint":false},{"pmid":"34750385","id":"PMC_34750385","title":"Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34750385","citation_count":59,"is_preprint":false},{"pmid":"32028068","id":"PMC_32028068","title":"Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.","date":"2020","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/32028068","citation_count":56,"is_preprint":false},{"pmid":"26298772","id":"PMC_26298772","title":"A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26298772","citation_count":55,"is_preprint":false},{"pmid":"38172595","id":"PMC_38172595","title":"4-1BB immunotherapy: advances and hurdles.","date":"2024","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38172595","citation_count":54,"is_preprint":false},{"pmid":"16924475","id":"PMC_16924475","title":"Dual immunoregulatory pathways of 4-1BB signaling.","date":"2006","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/16924475","citation_count":52,"is_preprint":false},{"pmid":"31201235","id":"PMC_31201235","title":"CD137 (4-1BB) Engagement Fine-Tunes Synergistic IL-15- and IL-21-Driven NK Cell Proliferation.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/31201235","citation_count":52,"is_preprint":false},{"pmid":"10843756","id":"PMC_10843756","title":"Expression of soluble CD137 correlates with activation-induced cell death of lymphocytes.","date":"2000","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/10843756","citation_count":52,"is_preprint":false},{"pmid":"19273343","id":"PMC_19273343","title":"CD137, implications in immunity and potential for therapy.","date":"2009","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/19273343","citation_count":51,"is_preprint":false},{"pmid":"10850651","id":"PMC_10850651","title":"4-1BB: still in the midst of darkness.","date":"2000","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/10850651","citation_count":51,"is_preprint":false},{"pmid":"15181282","id":"PMC_15181282","title":"Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.","date":"2004","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/15181282","citation_count":50,"is_preprint":false},{"pmid":"15998581","id":"PMC_15998581","title":"Genetic and functional association of the immune signaling molecule 4-1BB (CD137/TNFRSF9) with type 1 diabetes.","date":"2005","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/15998581","citation_count":49,"is_preprint":false},{"pmid":"31871298","id":"PMC_31871298","title":"4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31871298","citation_count":49,"is_preprint":false},{"pmid":"36185242","id":"PMC_36185242","title":"4-1BB: A promising target for cancer immunotherapy.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36185242","citation_count":46,"is_preprint":false},{"pmid":"12847221","id":"PMC_12847221","title":"Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12847221","citation_count":46,"is_preprint":false},{"pmid":"24667959","id":"PMC_24667959","title":"4-1BB chimeric antigen receptors.","date":"2014","source":"Cancer journal (Sudbury, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/24667959","citation_count":44,"is_preprint":false},{"pmid":"32355275","id":"PMC_32355275","title":"Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.","date":"2020","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32355275","citation_count":44,"is_preprint":false},{"pmid":"29133290","id":"PMC_29133290","title":"CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes.","date":"2017","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/29133290","citation_count":41,"is_preprint":false},{"pmid":"8612300","id":"PMC_8612300","title":"4-1BB is expressed on CD45RAhiROhi transitional T cell in humans.","date":"1996","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8612300","citation_count":40,"is_preprint":false},{"pmid":"7622190","id":"PMC_7622190","title":"Characterization of human homologue of 4-1BB and its ligand.","date":"1995","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/7622190","citation_count":39,"is_preprint":false},{"pmid":"13130507","id":"PMC_13130507","title":"Expression of CD137 and its ligand in human neurons, astrocytes, and microglia: modulation by FGF-2.","date":"2003","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/13130507","citation_count":39,"is_preprint":false},{"pmid":"34021248","id":"PMC_34021248","title":"CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity.","date":"2021","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/34021248","citation_count":38,"is_preprint":false},{"pmid":"16041031","id":"PMC_16041031","title":"4-1BB (CD137) is required for rapid clearance of Listeria monocytogenes infection.","date":"2005","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16041031","citation_count":38,"is_preprint":false},{"pmid":"25404362","id":"PMC_25404362","title":"4-1BB ligand signaling to T cells limits T cell activation.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25404362","citation_count":37,"is_preprint":false},{"pmid":"32161196","id":"PMC_32161196","title":"Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32161196","citation_count":36,"is_preprint":false},{"pmid":"32505443","id":"PMC_32505443","title":"CD137 / CD137 ligand signalling regulates the immune balance: A potential target for novel immunotherapy of autoimmune diseases.","date":"2020","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/32505443","citation_count":34,"is_preprint":false},{"pmid":"34172583","id":"PMC_34172583","title":"Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34172583","citation_count":34,"is_preprint":false},{"pmid":"36215121","id":"PMC_36215121","title":"Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.","date":"2022","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/36215121","citation_count":33,"is_preprint":false},{"pmid":"33530328","id":"PMC_33530328","title":"CD137+ T-Cells: Protagonists of the Immunotherapy Revolution.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33530328","citation_count":32,"is_preprint":false},{"pmid":"14614331","id":"PMC_14614331","title":"Tumor expression of 4-1BB ligand sustains tumor lytic T cells.","date":"2003","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/14614331","citation_count":32,"is_preprint":false},{"pmid":"26428392","id":"PMC_26428392","title":"Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies.","date":"2015","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/26428392","citation_count":31,"is_preprint":false},{"pmid":"34580116","id":"PMC_34580116","title":"CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function.","date":"2021","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/34580116","citation_count":28,"is_preprint":false},{"pmid":"29571029","id":"PMC_29571029","title":"CD137: A checkpoint regulator involved in atherosclerosis.","date":"2018","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/29571029","citation_count":26,"is_preprint":false},{"pmid":"34277638","id":"PMC_34277638","title":"Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34277638","citation_count":26,"is_preprint":false},{"pmid":"20610645","id":"PMC_20610645","title":"Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20610645","citation_count":26,"is_preprint":false},{"pmid":"33800462","id":"PMC_33800462","title":"Role of ADAM10 and ADAM17 in Regulating CD137 Function.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33800462","citation_count":25,"is_preprint":false},{"pmid":"12662292","id":"PMC_12662292","title":"Expression of CD137 (4-1BB) on human follicular dendritic cells.","date":"2003","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12662292","citation_count":25,"is_preprint":false},{"pmid":"16596186","id":"PMC_16596186","title":"Expression of CD137 and CD137 ligand in colorectal cancer patients.","date":"2006","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/16596186","citation_count":24,"is_preprint":false},{"pmid":"32149463","id":"PMC_32149463","title":"Exosome derived from CD137-modified endothelial cells regulates the Th17 responses in atherosclerosis.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32149463","citation_count":24,"is_preprint":false},{"pmid":"35236742","id":"PMC_35236742","title":"Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35236742","citation_count":23,"is_preprint":false},{"pmid":"37334375","id":"PMC_37334375","title":"Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37334375","citation_count":22,"is_preprint":false},{"pmid":"37662949","id":"PMC_37662949","title":"Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37662949","citation_count":21,"is_preprint":false},{"pmid":"29720399","id":"PMC_29720399","title":"Crystal structure of the human 4-1BB/4-1BBL complex.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29720399","citation_count":21,"is_preprint":false},{"pmid":"25520217","id":"PMC_25520217","title":"Natural Killer Cell Functional Activity After 4-1BB Costimulation.","date":"2015","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/25520217","citation_count":20,"is_preprint":false},{"pmid":"26587331","id":"PMC_26587331","title":"Functional expression of CD137 (4-1BB) on T helper follicular cells.","date":"2015","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/26587331","citation_count":19,"is_preprint":false},{"pmid":"31288851","id":"PMC_31288851","title":"Regulation of CD137 expression through K-Ras signaling in pancreatic cancer cells.","date":"2019","source":"Cancer communications (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31288851","citation_count":19,"is_preprint":false},{"pmid":"12460192","id":"PMC_12460192","title":"Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes.","date":"2002","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12460192","citation_count":19,"is_preprint":false},{"pmid":"38937625","id":"PMC_38937625","title":"4-1BB-encoding CAR causes cell death via sequestration of the ubiquitin-modifying enzyme A20.","date":"2024","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38937625","citation_count":18,"is_preprint":false},{"pmid":"33796637","id":"PMC_33796637","title":"Interstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP).","date":"2021","source":"European journal of radiology open","url":"https://pubmed.ncbi.nlm.nih.gov/33796637","citation_count":18,"is_preprint":false},{"pmid":"16101383","id":"PMC_16101383","title":"The therapeutic potential of 4-1BB (CD137) in cancer.","date":"2005","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/16101383","citation_count":18,"is_preprint":false},{"pmid":"32247042","id":"PMC_32247042","title":"CD137 signaling induces macrophage M2 polarization in atherosclerosis through STAT6/PPARδ pathway.","date":"2020","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/32247042","citation_count":18,"is_preprint":false},{"pmid":"9536288","id":"PMC_9536288","title":"Differentiation-dependent and stimulus-specific expression of ILA, the human 4-1BB-homologue, in cells of mesenchymal origin.","date":"1997","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/9536288","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45575,"output_tokens":6650,"usd":0.118237,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15866,"output_tokens":4894,"usd":0.10084,"stage2_stop_reason":"end_turn"},"total_usd":0.219077,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"4-1BB is a 30-kDa glycoprotein that exists as both a monomer and a 55-kDa dimer on the T cell surface; cross-linking of 4-1BB on anti-CD3-stimulated T cells dramatically enhanced T cell proliferation, demonstrating its function as an accessory costimulatory signaling molecule.\",\n      \"method\": \"mAb generation against recombinant soluble 4-1BB, SDS-PAGE, FACS analysis, T cell proliferation assay with cross-linking\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct biochemical characterization (molecular weight, glycoprotein, dimer/monomer), functional cross-linking assay, replicated in multiple T cell types\",\n      \"pmids\": [\"7678621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Human 4-1BB binds its ligand (4-1BBL) with high affinity (Scatchard analysis); ligation of 4-1BB on T cell clones enhanced activation-induced cell death when triggered alongside TCR/CD3 engagement, whereas mitogen co-stimulation induced strong proliferation.\",\n      \"method\": \"Molecular cloning, Fc-fusion protein binding assay, Scatchard analysis, proliferation and cell death assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — Scatchard binding quantification, functional proliferation and cell death assays in primary T cells, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"8088337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Human 4-1BB signals are mediated through TRAF1, TRAF2, and TRAF3, which bind to two runs of acidic residues in the cytoplasmic domain of 4-1BB; 4-1BB cross-linking or overexpression activates NF-κB via a TRAF2/NIK pathway, as shown by dominant-negative TRAF2 and NIK inhibition.\",\n      \"method\": \"Co-immunoprecipitation, mutation analysis of cytoplasmic domain, NF-κB reporter assay in Jurkat and 293 cells, dominant-negative constructs\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — site-directed mutagenesis of binding residues, dominant-negative constructs, NF-κB reporter assay, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"9464265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"4-1BB (CD137) signaling on monocytes induces expression of IL-6, IL-8, and TNF-α, inhibits IL-10, upregulates ICAM, and reduces FcγRIII expression; these effects require immobilized (cross-linked) CD137 protein, indicating they are mediated through a ligand/co-receptor on monocytes — establishing bidirectional signaling.\",\n      \"method\": \"Cytokine ELISA, flow cytometry for surface receptors, cross-linking assay with immobilized CD137 protein on primary human monocytes\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional readout with cytokine production and surface marker changes, cross-linking requirement shown, single lab with multiple cytokine endpoints\",\n      \"pmids\": [\"9498794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The 4-1BB signal synergized with CD28 co-stimulation to lower the threshold for T cell activation and IL-2 production; 4-1BB signaling skewed cytokine profiles toward Th1 (markedly enhanced IFN-γ) and suppressed Th2-type cytokines, preferentially in 4-1BB-expressing cells.\",\n      \"method\": \"T cell co-stimulation assays, intracellular cytokine staining for IFN-γ, cytokine ELISA, flow cytometry\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional assay with intracellular cytokine detection, multiple cytokine endpoints, single lab\",\n      \"pmids\": [\"9541583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Soluble CD137 (sCD137) expression lags behind membrane-bound CD137 by ~24 h; sCD137 levels correlate negatively with lymphocyte proliferation and positively with activation-induced cell death, suggesting sCD137 may provide a negative regulatory mechanism for immune responses.\",\n      \"method\": \"Time-course analysis of sCD137 by ELISA, correlation with proliferation assay and activation-induced cell death\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — correlation analysis with multiple time points and functional outcomes, single lab, no mechanistic intervention experiment\",\n      \"pmids\": [\"10843756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CD137 is constitutively expressed on primary human monocytes; cross-linking of CD137 on monocytes induces IL-8 and TNF-α production, inhibits IL-10, and causes B lymphocyte apoptosis via direct cell–cell contact.\",\n      \"method\": \"Flow cytometry, ELISA for cytokines, cell–cell contact co-culture apoptosis assay\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cross-linking experiment, cytokine measurement, B cell apoptosis assay, single lab with multiple endpoints\",\n      \"pmids\": [\"10607752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"4-1BB-deficient mice develop normally but show enhanced T cell proliferation to mitogens/anti-CD3, reduced cytokine production (IL-2, IL-4), diminished CTL activity, and altered myeloid progenitor growth, indicating 4-1BB costimulation is required for normal T cell effector function but restrains proliferation.\",\n      \"method\": \"Genetic knockout mouse model, in vitro T cell proliferation assay, cytokine ELISA, CTL assay, bone marrow/spleen cell analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with defined cellular phenotypes, multiple orthogonal functional readouts, single rigorous study\",\n      \"pmids\": [\"12023342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"4-1BBL is expressed on activated B cells, macrophages, and dendritic cells but not on T cells; 4-1BB is constitutively expressed on splenic dendritic cells and inducible on T cells; 4-1BBL stimulation of dendritic cells leads to IL-6 and IL-12 production and upregulation of co-stimulatory molecules.\",\n      \"method\": \"Flow cytometry with anti-4-1BB and anti-4-1BBL mAbs, co-culture experiments, cytokine ELISA\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct antibody staining and functional co-culture assays, newly generated blocking mAb, single lab\",\n      \"pmids\": [\"11867564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Anti-4-1BB agonist antibody treatment suppressed collagen-induced arthritis by inducing expansion of CD11c+CD8+ T cells; IFN-γ produced by these cells suppressed antigen-specific CD4+ T cells through an indoleamine 2,3-dioxygenase (IDO)-dependent mechanism, as shown by anti-IFN-γ and 1-methyltryptophan reversal.\",\n      \"method\": \"In vivo murine CIA model, antibody treatment, IDO inhibitor (1-methyltryptophan), anti-IFN-γ blocking, flow cytometry for T cell subsets\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic and pharmacological interventions, multiple orthogonal mechanistic tools (IDO inhibitor + anti-IFN-γ), established cell subset expansion\",\n      \"pmids\": [\"15448685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"4-1BB (CD137) is required for rapid clearance of Listeria monocytogenes; 4-1BB-deficient mice showed impaired neutrophil reactive oxygen species generation, phagocytosis, and intracellular Ca2+ mobilization; 4-1BB ligation on neutrophils induced Ca2+ influx.\",\n      \"method\": \"4-1BB KO mice, bacterial infection model, ROS assay, phagocytosis assay, Ca2+ influx measurement, anti-4-1BB mAb treatment\",\n      \"journal\": \"Infection and immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO plus antibody agonism, multiple functional neutrophil readouts, in vivo bacterial burden quantification\",\n      \"pmids\": [\"16041031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"4-1BB signaling in the periphery negatively regulates NK cell development through IFN-γ produced by peripheral CD8+ T and NK cells; this IFN-γ suppresses NK cell development in the bone marrow, shifting antitumor immunity from innate NK cell to adaptive CD8+ T cell dominance.\",\n      \"method\": \"4-1BB KO mice, tumor challenge models, flow cytometry for NK cell frequency in spleen/bone marrow, IFN-γ neutralization\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO, IFN-γ neutralization in vivo, cellular analysis in multiple compartments, mechanistic pathway established\",\n      \"pmids\": [\"20610645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Tonic 4-1BB signaling in CAR-T cells causes T cell toxicity via continuous TRAF2-dependent NF-κB activation and augmented FAS-dependent cell death; this was amplified by non-self-inactivating gammaretroviral vectors through positive feedback on the LTR promoter.\",\n      \"method\": \"CAR-T cell cultures, NF-κB reporter assay, TRAF2 knockdown, FAS pathway analysis, comparison of lentiviral vs. retroviral vectors\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway defined via TRAF2 knockdown, NF-κB activation assay, FAS pathway analysis, vector comparison, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"28978471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"4-1BB (CD137) costimulation induces mitochondrial enlargement, increasing mitochondrial mass and transmembrane potential in CD8+ T cells; this depends on mitochondrial fusion protein OPA-1 expression, enhances respiratory capacity, and is required for anti-tumor efficacy in adoptive T cell therapy.\",\n      \"method\": \"Mitochondrial staining (MitoTracker), transmission electron microscopy, OPA-1 knockout cells, oxygen consumption assay, in vivo adoptive transfer tumor model\",\n      \"journal\": \"Cancer immunology research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — OPA-1 genetic requirement established, metabolic measurements, in vivo functional readout, multiple orthogonal methods in single study\",\n      \"pmids\": [\"29678874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"4-1BB enhancement of CAR-T cell function is driven by NF-κB activation; TRAF1 and TRAF3 (in addition to TRAF2) are critical for 4-1BB costimulation in CAR-T cells, impacting viability, proliferation, cytotoxicity, and cytokine production.\",\n      \"method\": \"TRAF knockdown in CD19-CAR T cells, NF-κB reporter assay, cytotoxicity assay, cytokine ELISA, proliferation assay\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — TRAF knockdown experiments for each TRAF family member, NF-κB reporter, multiple functional readouts, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"30232281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Activation of 4-1BB on liver myeloid cells (Kupffer cells and monocytes) is essential to initiate 4-1BB agonist-induced hepatitis; these cells produce IL-27 required for liver toxicity; CD8+ T cells then infiltrate and mediate tissue damage; FoxP3+ Tregs limit damage.\",\n      \"method\": \"Immunocompetent mice with KO for specific cytokines/chemokines, flow cytometry, serum transaminase measurement, in vivo depletion studies, CCR2-KO mice\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple KO models, specific cytokine/chemokine pathway identified, cell subset depletion, mechanistic pathway established in vivo\",\n      \"pmids\": [\"29301830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The crystal structure of the human 4-1BB/4-1BBL complex at 2.4-Å resolution shows 4-1BBL forms a canonical bell-shaped trimer typical of TNF superfamily members (not the unusual three-bladed propeller reported previously); mutational data confirmed biological relevance of this structure.\",\n      \"method\": \"X-ray crystallography at 2.4-Å resolution, site-directed mutagenesis to validate interface\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with functional mutagenesis validation, definitive structural determination\",\n      \"pmids\": [\"29720399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CD137/4-1BB deficiency (homozygous biallelic loss-of-function mutation G109S abolishing protein expression) resulted in impaired CD8+ T cell expansion, reduced IFN-γ and perforin expression, diminished cytotoxicity against EBV-B cells, and significantly reduced mitochondrial biogenesis, membrane potential, and function in activated T cells.\",\n      \"method\": \"Whole-exome sequencing, immunoblotting, immunophenotyping, in vitro cytotoxicity assays, mitochondrial function assays, inhibitory antibody recapitulation experiments\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human loss-of-function mutation, multiple orthogonal functional and metabolic assays, antibody recapitulation confirming mechanistic specificity\",\n      \"pmids\": [\"30872117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PIK3CD and TNFRSF9 (CD137) deficiency together cause chronic active EBV infection of T cells; isolated CD137 deficiency caused persistent EBV-infected T cells, demonstrating CD137 is specifically required for controlling EBV-infected T cell accumulation via T cell expansion through the CD137-CD137L pathway.\",\n      \"method\": \"Genetic sequencing identifying biallelic loss-of-function mutations, flow cytometry, in vitro T cell expansion assay with CD137L-expressing cells\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human genetic loss-of-function, sibling comparison (isolated CD137 deficiency), functional T cell expansion assay, clear pathway placement\",\n      \"pmids\": [\"31537641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Oncogenic K-Ras upregulates CD137 in pancreatic cancer cells through activation of MAPK and NF-κB pathways, with NF-κB being mainly stimulated by K-Ras-induced IL-1α secretion that promotes CD137 gene transcription.\",\n      \"method\": \"Inducible K-RasG12V expression system, siRNA knockdown of MAPK1 and p65, RT-PCR, flow cytometry, ELISA\",\n      \"journal\": \"Cancer communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible expression system and siRNA knockdown with multiple pathway inhibitions, single lab, in vitro model\",\n      \"pmids\": [\"31288851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CD137 costimulation provided in cis (on the same cell as TCR-CD3 ligation) is superior to trans costimulation in terms of T cell activation, proliferation, survival, cytokine secretion, and mitochondrial fitness; cis CD137 ligation results in more intense canonical and non-canonical NF-κB signaling and stronger induction of cell cycle and DNA damage repair gene expression.\",\n      \"method\": \"Side-by-side comparison of cis vs. trans CD137 costimulation in vitro and in vivo, NF-κB signaling assays, gene expression profiling, mitochondrial fitness assays in mouse and human T cells\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — controlled side-by-side comparison, NF-κB pathway measurement, in vivo validation, replicated in mouse and human, multiple orthogonal endpoints\",\n      \"pmids\": [\"34911975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CD137 stimulation enhances tumoricidal activity of human monocytes/macrophages through an ERK-dependent mechanism, inducing metabolic reprogramming and a functional skewing toward M1-like phenotype; CD137-high monocytes show increased antibody-dependent phagocytosis.\",\n      \"method\": \"Flow cytometry, transcriptomic analysis, ERK inhibition, phagocytosis assay, metabolic profiling of primary human monocytes\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ERK inhibitor mechanistic experiment, functional phagocytosis and metabolic assays, transcriptomic analysis, single lab\",\n      \"pmids\": [\"34021248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ADAM10 (and potentially ADAM17) mediates ectodomain shedding of CD137 to generate soluble CD137 (sCD137); inhibition of ADAM10 uniformly blocked sCD137 release from transfected cell lines and primary T cells; phosphatidylserine exposure (controlled by ANO6 scramblase) modulates ADAM10-dependent shedding.\",\n      \"method\": \"ADAM10 inhibitors, ANO6 overexpression, sCD137 ELISA, primary T cell experiments\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition and overexpression experiments, multiple cell systems, single lab\",\n      \"pmids\": [\"33800462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"T cell-intrinsic, TCR-independent CD137 signaling stimulates proliferation and terminal differentiation of exhausted CD8+ T (Tex) precursor cells through RelA and cRel canonical NF-κB subunits and Tox-dependent chromatin remodeling.\",\n      \"method\": \"T cell-specific CD137 deletion (genetic KO), agonist antibody treatment, NF-κB subunit analysis (RelA, cRel), chromatin accessibility assay, flow cytometry for exhaustion markers in mouse tumor models\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — T cell-specific genetic deletion, NF-κB subunit identification, Tox chromatin remodeling mechanism, multiple orthogonal approaches in single rigorous study\",\n      \"pmids\": [\"37392737\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"4-1BB incorporated within CAR constructs sequesters the ubiquitin-modifying enzyme A20 to the cell membrane in a TRAF-dependent manner, causing A20 functional deficiency that leads to NF-κB hyperactivity, ICAM-1 overexpression, cell aggregation, and cell death via RIPK1/RIPK3/MLKL necroptosis pathway; overexpressing A20 or deleting TRAF-binding motifs of 4-1BB rescued this phenotype.\",\n      \"method\": \"Mechanistic studies with A20 overexpression, deletion of TRAF-binding motifs in 4-1BB, co-immunoprecipitation, NF-κB reporter assay, RIPK1/RIPK3/MLKL pathway analysis, cell death and aggregation assays\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — site-directed mutagenesis of TRAF-binding motifs, A20 overexpression rescue, Co-IP for complex formation, multiple mechanistic readouts, single lab with orthogonal approaches\",\n      \"pmids\": [\"38937625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"4-1BBL expressed on T cells can transmit reverse signals that limit T cell effector activity; cross-linking 4-1BBL inhibited IL-2 production, and APC-derived 4-1BB triggers 4-1BBL on T cells; T cell-intrinsic 4-1BB regulated internalization of membrane 4-1BBL, controlling the suppressive function of 4-1BBL.\",\n      \"method\": \"4-1BBL-deficient T cell transfers, 4-1BB-deficient host experiments, in vitro cross-linking assay, Ab capture and endocytosis experiments, flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO host and T cell transfers, endocytosis experiments, multiple orthogonal approaches, single lab\",\n      \"pmids\": [\"25404362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CD137 costimulation with agonist mAb (including urelumab) induces genome-wide DNA methylation changes in human CD8+ T cells, altering expression of immune-related genes including CD96, HHLA2, CCR5, CXCR5, and CCL5, as well as TCF1 transcription factor and miR-21 via methylation-dependent regulation.\",\n      \"method\": \"Genome-wide DNA methylation arrays, pyrosequencing validation, mRNA and protein expression analysis in human peripheral blood CD8+ T cells\",\n      \"journal\": \"Cancer immunology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide methylation arrays plus pyrosequencing validation across multiple donors, mRNA/protein confirmation, single lab\",\n      \"pmids\": [\"29133290\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFRSF9/CD137/4-1BB is an activation-inducible TNFR superfamily receptor that lacks intrinsic kinase activity and signals through recruitment of TRAF1, TRAF2, and TRAF3 to acidic residues in its cytoplasmic domain, activating canonical NF-κB via TRAF2/NIK, driving T cell survival, proliferation, Th1 cytokine production, and mitochondrial biogenesis (dependent on OPA-1-mediated fusion); it also undergoes ADAM10-mediated ectodomain shedding to produce soluble CD137, and engages in bidirectional signaling where 4-1BBL reverse signaling into APCs and T cells can limit T cell activation; in CAR-T cells, ectopic 4-1BB domain sequesters A20 in a TRAF-dependent manner, causing NF-κB hyperactivity and necroptosis via RIPK1/RIPK3/MLKL, while in exhausted T cells TCR-independent CD137 signaling drives proliferation and terminal differentiation through RelA/cRel NF-κB and Tox-dependent chromatin remodeling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TNFRSF9 (4-1BB/CD137) is an activation-inducible TNF receptor superfamily costimulatory receptor that amplifies T cell effector responses upon engagement of its ligand 4-1BBL [#0, #1, #16]. Lacking intrinsic enzymatic activity, the receptor signals through its cytoplasmic domain, where two runs of acidic residues recruit TRAF1, TRAF2, and TRAF3 to drive canonical NF-\\u03baB activation via a TRAF2/NIK axis [#2], and all three TRAFs contribute to its costimulatory output [#14]. Productive signaling lowers the threshold for T cell activation in synergy with CD28, skews cytokines toward Th1 (notably IFN-\\u03b3), supports CD8+ T cell expansion and cytotoxicity, and reprograms metabolism by inducing OPA-1-dependent mitochondrial biogenesis and respiratory capacity [#4, #13, #20]. Costimulation delivered in cis (on the same cell as TCR-CD3 ligation) produces more intense canonical and non-canonical NF-\\u03baB signaling than trans engagement [#20], and TCR-independent CD137 signaling drives proliferation and terminal differentiation of exhausted CD8+ T cells through RelA/cRel NF-\\u03baB and Tox-dependent chromatin remodeling [#23]. The receptor also acts beyond T cells: it is constitutively expressed on monocytes and signals bidirectionally to induce inflammatory cytokines and macrophage tumoricidal activity [#3, #6, #21], and it is required for normal neutrophil microbicidal function [#10]. Biallelic loss-of-function mutations in TNFRSF9 abolish protein expression and cause defective CD8+ T cell expansion, cytotoxicity, and mitochondrial function, manifesting as failure to control EBV-infected T cells (chronic active EBV infection) [#17, #18]. The receptor undergoes ADAM10-mediated ectodomain shedding to generate soluble CD137 [#22], and within CAR-T constructs the 4-1BB domain can drive toxicity by TRAF-dependent sequestration of A20, producing NF-\\u03baB hyperactivity and RIPK1/RIPK3/MLKL necroptosis [#12, #24].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established that 4-1BB is a cell-surface glycoprotein on T cells whose cross-linking costimulates proliferation, defining it as an accessory signaling molecule rather than a passive marker.\",\n      \"evidence\": \"mAb generation, SDS-PAGE/FACS biochemistry, and T cell proliferation assays with cross-linking\",\n      \"pmids\": [\"7678621\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand identity and binding affinity not yet defined\", \"No intracellular signaling pathway identified\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Quantified high-affinity 4-1BB/4-1BBL binding and showed signaling outcome is context-dependent, enhancing proliferation under mitogen but augmenting activation-induced cell death with TCR engagement.\",\n      \"evidence\": \"Cloning, Fc-fusion binding with Scatchard analysis, proliferation and cell death assays in primary T cells\",\n      \"pmids\": [\"8088337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of the proliferation-versus-death switch unresolved\", \"Downstream signaling effectors not identified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defined the proximal signaling mechanism, showing acidic cytoplasmic residues recruit TRAF1/2/3 to activate NF-\\u03baB through TRAF2/NIK, placing 4-1BB in the canonical TNFR signaling framework.\",\n      \"evidence\": \"Co-IP, cytoplasmic-domain mutagenesis, NF-\\u03baB reporter and dominant-negative TRAF2/NIK in Jurkat and 293 cells\",\n      \"pmids\": [\"9464265\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of individual TRAFs not separated\", \"Non-canonical NF-\\u03baB role not addressed\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Extended 4-1BB function to costimulatory quality and beyond T cells, showing synergy with CD28, Th1 cytokine skewing, and bidirectional signaling that activates monocytes through a co-receptor on those cells.\",\n      \"evidence\": \"Intracellular cytokine staining, ELISA, and cross-linking with immobilized CD137 on primary monocytes\",\n      \"pmids\": [\"9541583\", \"9498794\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Monocyte counter-receptor for CD137 not molecularly identified\", \"Bidirectional signaling components on monocytes undefined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified soluble CD137 as a delayed, potentially negative regulatory output correlating with reduced proliferation and increased activation-induced cell death.\",\n      \"evidence\": \"Time-course sCD137 ELISA correlated with proliferation and cell death readouts\",\n      \"pmids\": [\"10843756\", \"10607752\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No causal intervention demonstrating sCD137 function\", \"Protease generating sCD137 not yet identified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Genetic loss-of-function in mice resolved the in vivo physiological role, showing 4-1BB is required for normal effector cytokine production and CTL activity while paradoxically restraining proliferation.\",\n      \"evidence\": \"4-1BB knockout mice with proliferation, cytokine, CTL, and myeloid progenitor assays\",\n      \"pmids\": [\"12023342\", \"11867564\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type-specific contributions not dissected\", \"Mechanism of proliferation restraint unexplained\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated a non-T-cell innate role, with 4-1BB required for neutrophil ROS production, phagocytosis, and calcium mobilization for bacterial clearance.\",\n      \"evidence\": \"4-1BB KO mice in Listeria infection with ROS, phagocytosis, and Ca2+ assays plus agonist mAb\",\n      \"pmids\": [\"16041031\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Neutrophil signaling pathway downstream of 4-1BB not defined\", \"Ligand source in vivo not established\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed 4-1BB shapes immune-compartment balance, with peripheral signaling driving IFN-\\u03b3 that suppresses bone marrow NK development and shifts antitumor immunity toward CD8+ T cells.\",\n      \"evidence\": \"4-1BB KO mice, tumor challenge, compartmental flow cytometry, IFN-\\u03b3 neutralization\",\n      \"pmids\": [\"20610645\", \"15448685\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect effects on NK progenitors not separated\", \"IDO/IFN-\\u03b3 regulatory circuit in other settings not generalized\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked 4-1BB costimulation to metabolic reprogramming, establishing OPA-1-dependent mitochondrial biogenesis and respiratory capacity as required for antitumor T cell efficacy.\",\n      \"evidence\": \"MitoTracker, electron microscopy, OPA-1 knockout, oxygen consumption, and adoptive transfer tumor model\",\n      \"pmids\": [\"29678874\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling link from NF-\\u03baB to OPA-1 not mapped\", \"Whether shedding regulates this metabolic program unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved the structural basis of receptor-ligand engagement, showing 4-1BBL forms a canonical TNF-superfamily bell-shaped trimer, correcting an earlier propeller model.\",\n      \"evidence\": \"2.4-\\u00c5 X-ray crystallography of the 4-1BB/4-1BBL complex with interface mutagenesis\",\n      \"pmids\": [\"29720399\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of higher-order signaling clusters not defined\", \"Conformational changes transmitting signal to cytoplasm not shown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established human disease causality, with biallelic loss-of-function mutations abolishing CD137 expression and producing defective CD8+ T cell expansion, cytotoxicity, mitochondrial function, and failure to control EBV-infected T cells.\",\n      \"evidence\": \"Whole-exome sequencing, immunoblotting, cytotoxicity and mitochondrial assays, antibody recapitulation, and T cell expansion with CD137L-expressing cells\",\n      \"pmids\": [\"30872117\", \"31537641\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific consequences beyond T cells in patients not characterized\", \"Genetic interaction with PIK3CD not fully separated in all cases\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed an epigenetic dimension to CD137 costimulation, showing agonist signaling reprograms genome-wide DNA methylation to alter immune-gene and transcription-factor expression.\",\n      \"evidence\": \"Genome-wide methylation arrays with pyrosequencing and mRNA/protein validation in human CD8+ T cells\",\n      \"pmids\": [\"29133290\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enzymes mediating methylation changes not identified\", \"Causality between methylation and phenotype not fully demonstrated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Clarified signaling geometry and a defined shedding mechanism, showing cis costimulation outperforms trans and that ADAM10 mediates ectodomain shedding to generate soluble CD137 under phosphatidylserine-regulated control.\",\n      \"evidence\": \"Cis-versus-trans comparisons with NF-\\u03baB and mitochondrial assays; ADAM10 inhibitors and ANO6 overexpression with sCD137 ELISA\",\n      \"pmids\": [\"34911975\", \"33800462\", \"34021248\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological trigger of cis presentation in vivo not defined\", \"Function of sCD137 generated by ADAM10 not causally tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified a TCR-independent CD137 signaling program that drives proliferation and terminal differentiation of exhausted CD8+ T cells via RelA/cRel NF-\\u03baB and Tox-dependent chromatin remodeling.\",\n      \"evidence\": \"T cell-specific CD137 deletion, agonist treatment, NF-\\u03baB subunit analysis, and chromatin accessibility assays in mouse tumor models\",\n      \"pmids\": [\"37392737\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand source for TCR-independent signaling not defined\", \"Reversibility of Tox-driven terminal differentiation unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined a toxicity mechanism intrinsic to 4-1BB-containing CAR constructs, where TRAF-dependent membrane sequestration of A20 causes NF-\\u03baB hyperactivity and RIPK1/RIPK3/MLKL necroptosis.\",\n      \"evidence\": \"TRAF-binding motif deletion, A20 overexpression rescue, Co-IP, NF-\\u03baB reporter, and necroptosis pathway analysis in CAR-T cells\",\n      \"pmids\": [\"38937625\", \"28978471\", \"30232281\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Threshold of tonic signaling triggering necroptosis not quantified\", \"Whether native 4-1BB engages A20 similarly not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the receptor's signaling outputs are switched between costimulatory survival, activation-induced death, metabolic reprogramming, and necroptotic toxicity by ligand geometry, TRAF stoichiometry, and shedding remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model integrating cis/trans presentation with downstream effector choice\", \"Counter-receptor mediating monocyte bidirectional signaling unidentified\", \"Causal function of soluble CD137 in vivo undetermined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [1, 16]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 6, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 7, 23]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 14, 20]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TNFSF9\", \"TRAF1\", \"TRAF2\", \"TRAF3\", \"TNFAIP3\", \"ADAM10\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}